TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23904492

Group type: EXPERIMENTAL
Intervention: Reward expected and received
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reward expected but not received
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reward not expected and not received
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dopaminergic modulation (L-DOPA)
Number of subjects: 0
Study: 21757054

Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (84/7 days)
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Conventional regimen (21/7 days)
Number of subjects: 1315
Study: 17293790

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 50
Study: 16309769

Group type: EXPERIMENTAL
Intervention: Beta-radiation with 18 Gy at 1 mm vessel depth (n = 53)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo treatment (n = 53)
Number of subjects: 89
Study: 15266219

Group type: EXPERIMENTAL
Intervention: 3 mg granisetron
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 11677359

Group type: EXPERIMENTAL
Intervention: DASH diet (reduced in fats, emphasizes fruits, vegetables, and low-fat dairy products)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet (rich in fruits and vegetables, resembles control diet)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control diet (similar to typical American intake)
Number of subjects: 459
Study: 9882029

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PT)
Number of subjects: 48
Study: 8154035

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) 800 mg orally or 400 mg i.v. q.i.d. for 12 weeks after transplantation or 6 weeks after any antirejection therapy
Number of subjects: 311

Group type: COMPARATOR
Intervention: Ganciclovir (GCV) 5 mg/kg/12 hr i.v. for 7 days after transplant or after any antirejection therapy plus human immune globulin (HIg) 100 mg/kg i.v. administered on days 1, 4, and 7 after transplant or after any antirejection therapy
Number of subjects: 311
Study: 3138628

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 100
Study: 29221717

Group type: EXPERIMENTAL
Intervention: Metformin combined with therapeutic lifestyle changes (TLC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: TLC alone
Number of subjects: 64
Study: 26817789

Group type: EXPERIMENTAL
Intervention: Checklist
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Template
Number of subjects: 63

Group type: COMPARATOR
Intervention: No cognitive aid (Control)
Number of subjects: 63
Study: 25534864

Group type: EXPERIMENTAL
Intervention: Combined use of intravenous and topical tranexamic acid (TXA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 120
Study: 23064795

Group type: EXPERIMENTAL
Intervention: Tumor-positive SLN
Number of subjects: 509
Study: 20647171

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155U-195U)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study: 18249210

Group type: EXPERIMENTAL
Intervention: Normal-fat diet (25%)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-fat diet (60%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-fat diet (10%)
Number of subjects: 14
Study: 16801182

Group type: EXPERIMENTAL
Intervention: GosFos (1 g/100 mL)
Number of subjects: 20
Study: 14696738

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1450 ppm F
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Postal toothpaste programme
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no toothpaste)
Number of subjects: 9
Study: 10995002

Group type: EXPERIMENTAL
Intervention: Regimen B (L-asparaginase and intermediate-dose methotrexate)
Number of subjects: 1354

Group type: COMPARATOR
Intervention: Regimen C (cytarabine and intermediate-dose methotrexate)
Number of subjects: 1354

Group type: COMPARATOR
Intervention: Regimen C
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Regimen B
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 1354
Study: 8810562

Group type: EXPERIMENTAL
Intervention: MLPA test for detection of anti-PGL-1 antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slit skin smear method
Number of subjects: 0
Study: 8403676

Group type: EXPERIMENTAL
Intervention: Debridement and implantation of gentamicin‐polymethylmethacrylate (PMMA) beads
Number of subjects: 28

Group type: COMPARATOR
Intervention: Debridement and conventional parenteral systemic antibiotic therapy
Number of subjects: 28
Study: 3527946

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (400 mg 17-1A immunoglobulin, single dose, intravenous)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of monoclonal antibody and F.A.M. chemotherapy (5-fluorouracil, adriamycin, mitomycin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (after 8-week cycle of F.A.M. chemotherapy)
Number of subjects: 16

Group type: COMPARATOR
Intervention: F.A.M. chemotherapy
Number of subjects: 16
Study: 29796742

Group type: EXPERIMENTAL
Intervention: Quilting suture using the septum stitch device
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nasal silicone splint method
Number of subjects: 23
Study: 28076254

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 61

Group type: COMPARATOR
Intervention: Overall patient-centeredness
Number of subjects: 61
Study: 24618153

Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Docetaxel followed by eprirubicin/docetaxel (T-ET)
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: pCR
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Chemotherapy arm (T-ET)
Number of subjects: 1212
Study: 24026296

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (UG) technique
Number of subjects: 118

Group type: COMPARATOR
Intervention: Landmark (LM) technique
Number of subjects: 118

Group type: COMPARATOR
Intervention: Quick-look ultrasound with skin mark (UM) technique
Number of subjects: 118
Study: 20799126

Group type: COMPARATOR
Intervention: Hypnosis (year-long weekly group intervention)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 2
Study: 18855808

Group type: EXPERIMENTAL
Intervention: Focus on Families intervention (treatment-as-usual plus intervention)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Treatment-as-usual (control condition)
Number of subjects: 177
Study: 17407944

Group type: EXPERIMENTAL
Intervention: Nonimage-based navigation system
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 55
Study: 12597931

Group type: COMPARATOR
Intervention: Midazolam (2 mg administered intravenously 5 minutes before ESWL)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Music chosen by the patients listened to with a headset during treatment
Number of subjects: 98
Study: 11291604

Group type: EXPERIMENTAL
Intervention: Ganciclovir pre-emptive treatment
Number of subjects: 208

Group type: COMPARATOR
Intervention: Anti-thymocyte serum (ATG)
Number of subjects: 208

Group type: COMPARATOR
Intervention: None (control group lacking ATG)
Number of subjects: 208

Group type: COMPARATOR
Intervention: None (control group of blood/platelet donors)
Number of subjects: 208
Study: 9238868

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Interclean (ID2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Manual floss
Number of subjects: 52
Study: 1482267

Group type: EXPERIMENTAL
Intervention: Active treatment (N = 146)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo (N = 170)
Number of subjects: 316
Study: 6742647

Group type: EXPERIMENTAL
Intervention: Chenodiol (chenodeoxycholic acid)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study: 29781350

Group type: EXPERIMENTAL
Intervention: On-line ethics education module
Number of subjects: 33
Study: 30101524

Group type: EXPERIMENTAL
Intervention: Training intervention for owners on best practices to reduce workplace chemical exposures
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 200
Study: 27433356

Group type: EXPERIMENTAL
Intervention: Attending college
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: More lymph nodes removed
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: >25% BCRL care adherence
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Years since treatment
Number of subjects: 296

Group type: COMPARATOR
Intervention: Black race
Number of subjects: 296

Group type: COMPARATOR
Intervention: BMI
Number of subjects: 296
Study: 25275218

Group type: EXPERIMENTAL
Intervention: Beraprost (80 μg twice a day orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 22510238

Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg/day plus vardenafil 10 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: tamsulosin 0.4 mg/day
Number of subjects: 60
Study: 21095265

Group type: EXPERIMENTAL
Intervention: 24 months of clopidogrel therapy
Number of subjects: 1700

Group type: COMPARATOR
Intervention: 6 months of clopidogrel therapy
Number of subjects: 1700
Study: 18646528

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (16.7 mg/d)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (8.4 mg/d)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (5.6 mg/d)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (0.0 mg/d)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vitamin E (VE 5 mg/d)
Number of subjects: 300
Study: 15795365

Group type: EXPERIMENTAL
Intervention: Breathing 100% oxygen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Breathing 21% oxygen
Number of subjects: 36
Study: 12486649

Group type: EXPERIMENTAL
Intervention: hemoglobin raffimer (250 mL, 500 mL, or 750 mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hemoglobin raffimer (750 mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hemoglobin raffimer
Number of subjects: 60

Group type: COMPARATOR
Intervention: 6% hetastarch (control)
Number of subjects: 60
Study: 10367952

Group type: EXPERIMENTAL
Intervention: Vaqta 50 U/dose
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Vaqta 100 U/dose
Number of subjects: 520

Group type: COMPARATOR
Intervention: Havrix 1440 U/dose
Number of subjects: 520

Group type: COMPARATOR
Intervention: Havrix
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Vaqta and Havrix
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Vaqta
Number of subjects: 520
Study: 9454115

Group type: EXPERIMENTAL
Intervention: Total laryngectomy patients
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (N=30)
Number of subjects: 110
Study: 2350052

Group type: EXPERIMENTAL
Intervention: Multicomponent endotracheal anesthesia with neuroleptanalgesia and cardiopulmonary bypass, postoperative analgesia with non-narcotic and narcotic analgesics
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural anesthesia into upper chest segments with trimecaine + adrenaline and low morphine doses
Number of subjects: 60
Study: 789027

Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine (Mucodyne)
Number of subjects: 82
Study: 31761527

Group type: EXPERIMENTAL
Intervention: Received depression help-seeking message once
Number of subjects: 7017

Group type: EXPERIMENTAL
Intervention: Received depression help-seeking message twice
Number of subjects: 7017

Group type: COMPARATOR
Intervention: Never received depression help-seeking message
Number of subjects: 7017

Group type: EXPERIMENTAL
Intervention: Repeated exposure to the message
Number of subjects: 7017
Study: 30869025

Group type: EXPERIMENTAL
Intervention: PCR using species-specific 18S rRNA primers for the Entamoeba complex
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Microscopic stool examination
Number of subjects: 1383
Study: 28115837

Group type: EXPERIMENTAL
Intervention: Tai chi qigong (n=24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care control (n=24)
Number of subjects: 48
Study: 26394045

Group type: COMPARATOR
Intervention: PBA+vitD3
Number of subjects: 288

Group type: COMPARATOR
Intervention: vitD3
Number of subjects: 288

Group type: COMPARATOR
Intervention: PBA
Number of subjects: 288
Study: 23485730

Group type: EXPERIMENTAL
Intervention: Progressive agility and trunk stabilization rehabilitation program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Progressive running and eccentric strengthening rehabilitation program
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both rehabilitation programs
Number of subjects: 31
Study: 21871779

Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P seminars
Number of subjects: 53

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 53
Study: 19579092

Group type: EXPERIMENTAL
Intervention: Methadone treatment entry within four months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous drug use
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cocaine use moderation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heroin use among non-treatment entrants
Number of subjects: 120
Study: 17027823

Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling exercise training (900 kcal/week, 3-5 sessions per week, for 12 weeks)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Vigorous intensity cycling exercise training (900 kcal/week, 3-5 sessions per week, for 12 weeks)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Moderate and vigorous physical activity
Number of subjects: 103
Study: 12752398

Group type: EXPERIMENTAL
Intervention: Intramuscular infusion of a combination of bradykinin, serotonin, histamine, and prostaglandin E2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10841243

Group type: EXPERIMENTAL
Intervention: Intravenous heparin 6 h postoperatively
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intravenous heparin 24 h postoperatively
Number of subjects: 49

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 49

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 49
Study: 9506008

Group type: EXPERIMENTAL
Intervention: Testosterone transdermal system applied to upper buttocks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Testosterone transdermal system applied to upper arm
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Testosterone transdermal system applied to back
Number of subjects: 13
Study: 8432275

Group type: EXPERIMENTAL
Intervention: alfentanil 20 micrograms/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: lignocaine 1.5 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 45
Study: 3099487

Group type: EXPERIMENTAL
Intervention: 5 mg nitroglycerin per day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg nitroglycerin per day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28753047

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL) with guided reflection and feedback on the team leadership process
Number of subjects: 39

Group type: COMPARATOR
Intervention: Team-Based Learning (TBL) only
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pretest intervention group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pretest control group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Posttest intervention group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Posttest control group
Number of subjects: 39
Study: 27397669

Group type: EXPERIMENTAL
Intervention: Sniffing position with a pillow of 7 cm
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Elevated sniffing position with a pillow of 10 cm
Number of subjects: 18

Group type: COMPARATOR
Intervention: Simple head extension without a pillow
Number of subjects: 18
Study: 23939953

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)/TDF
Number of subjects: 585

Group type: COMPARATOR
Intervention: TDF monotherapy
Number of subjects: 585
Study: 22750852

Group type: EXPERIMENTAL
Intervention: High-calorie milkshake preload
Number of subjects: 118

Group type: COMPARATOR
Intervention: Non-caloric drink preload
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Food-reinforcement task
Number of subjects: 118
Study: 20009790

Group type: EXPERIMENTAL
Intervention: Preoperative sizing with silicone implant samples
Number of subjects: 567

Group type: COMPARATOR
Intervention: Control group (no preoperative sizing)
Number of subjects: 567
Study: 19213351

Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine treatment including Chinese recipe decoction (500 mL for hip bathing 5-10 min every night) and local application of Jingan oil (twice daily) for 2 months.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group treated with local application of Jingan oil and hip bathing with warm water for 2 months.
Number of subjects: 100
Study: 16078300

Group type: EXPERIMENTAL
Intervention: Rhomboid excision and the Limberg flap procedure (group 2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Excision and primary closure (group 1)
Number of subjects: 200
Study: 11839368

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10444121

Group type: EXPERIMENTAL
Intervention: Combined optical mechanical cystolithotripsy (OMC) and transurethral prostatectomy (TURP)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: OMC alone
Number of subjects: 61

Group type: COMPARATOR
Intervention: TURP alone (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined OMC and TURP
Number of subjects: 61
Study: 8595172

Group type: EXPERIMENTAL
Intervention: 3 mg of ZD1033 daily for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg of ZD1033 daily for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 mg of ZD1033 daily for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ACTH challenge
Number of subjects: 0
Study: 1815819

Group type: EXPERIMENTAL
Intervention: Mental inactivity (eyes closed)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mental arithmetics (eyes open)
Number of subjects: 10
Study: 6119492

Group type: EXPERIMENTAL
Intervention: Preoperative parenteral nutrition (PPN) for 10 days
Number of subjects: 125

Group type: COMPARATOR
Intervention: Regular hospital diet (Control)
Number of subjects: 125
Study: 31494273

Group type: EXPERIMENTAL
Intervention: 40 IU of oxytocin nasal spray
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 80
Study: 30999057

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 27492419

Group type: EXPERIMENTAL
Intervention: Nutrient-dense oral nutritional supplement (ONS) containing high protein and β-hydroxy-β-methylbutyrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrient-dense oral nutritional supplement (ONS)
Number of subjects: 0
Study: 26717219

Group type: EXPERIMENTAL
Intervention: Mozart music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Beatles music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radio news
Number of subjects: 60
Study: 23212610

Group type: EXPERIMENTAL
Intervention: CR665 (0.36 mg/kg, intravenous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg, oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (intravenous and oral)
Number of subjects: 0
Study: 21654521

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg intravenously on day 1 of the 2‐week cycle and IFN‐α thrice weekly at 5 MU/m subcutaneously during cycle 1, increased to 10 MU/m during cycle 2.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bevacizumab and IFN‐α combination therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: IFN‐α
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bevacizumab and IFN‐α
Number of subjects: 25
Study: 19344357

Group type: EXPERIMENTAL
Intervention: Synbiotic product containing antioxidative Lactobacillus fermentum ME‐3, Lact. paracasei 8700:2 and Bifidobacterium longum 46 with Raftilose P95
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 53
Study: 15811062

Group type: EXPERIMENTAL
Intervention: Vector device (n=16)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dentsply device at reduced power setting (n=22)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 38
Study: 12459402

Group type: EXPERIMENTAL
Intervention: Lead chelation therapy
Number of subjects: 111
Study: 10627736

Group type: EXPERIMENTAL
Intervention: Gentamicin 6 mg/kg once daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Gentamicin 5 mg/kg divided into twice daily doses
Number of subjects: 75
Study: 8654073

Group type: EXPERIMENTAL
Intervention: 0.5% Sodium Lauryl Sulfate (SLS) applied for 23 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3 concentrations of Dimethylsulfoxide (DMSO) and 0.2 mol/l NaOH applied for 5 minutes
Number of subjects: 20
Study: 1932669

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate (EO)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 5% sodium morrhuate (SM)
Number of subjects: 45
Study: 7255513

Group type: EXPERIMENTAL
Intervention: 300 mg fenoprofen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg fenoprofen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison with previous studies
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Haematological and biochemical values
Number of subjects: 10